Dataset from A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3).
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009930
下载链接
链接失效反馈官方服务：
资源简介：
A Phase III, Open Label, Randomized Study of Osimertinib versus Platinum-Based Doublet
Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase
Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth
Factor Receptor Gene
创建时间：
2025-08-05
